Last reviewed · How we verify
NCT06340412
Effects of Intact and Disrupted Milk Fat Globule Membrane on Postprandial Metabolic Response to High-fat Dairy in Healthy Individuals
NA trial testing Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch. in Postprandial Lipid Metabolism in 12 participants. Completed in 1 March 2025.
1 December 2024
Quick facts
| Lead sponsor | University of Aarhus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | crossover |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 12 |
| Start date | 11 March 2024 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.
- Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.
- Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.
Conditions studied
- Postprandial Lipid Metabolism — all drugs for Postprandial Lipid Metabolism →
Sponsor
University of Aarhus
Who can join
Adults 18 to 40, any sex, with Postprandial Lipid Metabolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to investigate the effects of milk fat globule membrane (MFGM) content and intactness on postprandial metabolic response to a high-fat meal in humans. The investigators hypothesize that MFGM content and intactness alters the postprandial lipid profile and substrate metabolism in healthy individuals after consumption of a high-fat meal.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Milk fat globule membrane in a novel high-fat spread does not acutely affect postprandial lipidemia in healthy individuals - A randomized, double-blind crossover trial.
Voigt JH, Zubanovic NB, Møller AB, Suwal SK, et al · · 2026 · PMID 42251897 · DOI 10.1016/j.tjnut.2026.101647
Verify or expand the search:
- PubMed search for NCT06340412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Aarhus trials
Trials by the same sponsor.
- NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
- NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
- NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
- NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06340412 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
- Last refreshed: 6 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06340412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing